Compass Pathways plc (CMPS) has faced significant risks since my last 'Buy' rating in January 2026. CMPS shares had declined approximately 10% over the intervening months, but then registered huge ...
Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. Developing therapies based on controlled substances involves unique risks, which Compass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results